These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Toll-like receptors in inflammation, infection and cancer. Chen K; Huang J; Gong W; Iribarren P; Dunlop NM; Wang JM Int Immunopharmacol; 2007 Oct; 7(10):1271-85. PubMed ID: 17673142 [TBL] [Abstract][Full Text] [Related]
46. TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Shibolet O; Podolsky DK Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1469-73. PubMed ID: 17554134 [TBL] [Abstract][Full Text] [Related]
47. Inflammatory pathways in malaria infection: TLRs share the stage with other components of innate immunity. Erdman LK; Finney CA; Liles WC; Kain KC Mol Biochem Parasitol; 2008 Dec; 162(2):105-11. PubMed ID: 18804125 [TBL] [Abstract][Full Text] [Related]
48. Toll-like receptors: emerging concepts in kidney disease. Anders HJ; Schlöndorff D Curr Opin Nephrol Hypertens; 2007 May; 16(3):177-83. PubMed ID: 17420659 [TBL] [Abstract][Full Text] [Related]
49. Update on the role of innate immune receptors during Brucella abortus infection. Oliveira SC; de Almeida LA; Carvalho NB; Oliveira FS; Lacerda TL Vet Immunol Immunopathol; 2012 Jul; 148(1-2):129-35. PubMed ID: 21700343 [TBL] [Abstract][Full Text] [Related]
50. Toll-Like receptors (TLRs) and their ligands. Uematsu S; Akira S Handb Exp Pharmacol; 2008; (183):1-20. PubMed ID: 18071652 [TBL] [Abstract][Full Text] [Related]
51. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. Li TT; Ogino S; Qian ZR World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469 [TBL] [Abstract][Full Text] [Related]
52. Toll-like receptors and innate immunity. Uematsu S; Akira S J Mol Med (Berl); 2006 Sep; 84(9):712-25. PubMed ID: 16924467 [TBL] [Abstract][Full Text] [Related]
53. Toll-like receptors (TLRs) in aquatic animals: signaling pathways, expressions and immune responses. Rauta PR; Samanta M; Dash HR; Nayak B; Das S Immunol Lett; 2014; 158(1-2):14-24. PubMed ID: 24291116 [TBL] [Abstract][Full Text] [Related]
54. TLR signalling and association of TLR polymorphism with cardiovascular diseases. Sharma S; Garg I; Ashraf MZ Vascul Pharmacol; 2016 Dec; 87():30-37. PubMed ID: 27826031 [TBL] [Abstract][Full Text] [Related]
55. Toll-like receptors in hepatitis C infection: implications for pathogenesis and treatment. Howell J; Angus P; Gow P; Visvanathan K J Gastroenterol Hepatol; 2013 May; 28(5):766-76. PubMed ID: 23432473 [TBL] [Abstract][Full Text] [Related]
56. Recent patents in Toll-like receptor pathways and relevance to cancer. Kimbro K; Parker S Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):189-95. PubMed ID: 19522696 [TBL] [Abstract][Full Text] [Related]
57. Toll-like receptors and their role in renal pathologies. Eleftheriadis T; Pissas G; Liakopoulos V; Stefanidis I; Lawson BR Inflamm Allergy Drug Targets; 2012 Dec; 11(6):464-77. PubMed ID: 22931389 [TBL] [Abstract][Full Text] [Related]
58. The innate immune response during liver inflammation and metabolic disease. Bieghs V; Trautwein C Trends Immunol; 2013 Sep; 34(9):446-52. PubMed ID: 23668977 [TBL] [Abstract][Full Text] [Related]
60. Role of Toll-like receptors in microbiota-associated gastrointestinal cancer metastasis. Lu Q; Ding H; Li W J Cancer Res Ther; 2013 Nov; 9 Suppl():S142-9. PubMed ID: 24516050 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]